Ask AI
ProCE Banner Activity

Expanding Therapeutic Horizons: Targeting Non-V600 BRAF Mutations in Solid Tumors

Clinical Thought

In this commentary, an expert addresses the importance of targeting non-V600 BRAF alterations in cancer and the emerging data on investigational agents targeting these alterations in patients.

Released: August 02, 2023

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Kinnate Biopharma.

Kinnate Biopharma

Faculty Disclosure

Primary Author

Alex Spira, MD, PhD, FACP

Director Clinical Research
Virginia Cancer Specialists
CEO NEXT Oncology Virginia
Fairfax, Virginia

Alexander Spira, MD, PhD, FACP: consultant: Amgen, Array, AstraZeneca/Medimmune, Bristol Myers Squibb, Gritstone Oncology, Incyte, Janssen, Jazz, Merck, Mirati, Novartis; researcher: AbbVie, ADCT, Amgen, Arch, Astellas, Astex, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo, Gritstone, Incyte, Ignyta, Janssen, LAM Therapeutics, Loxo, Macrogenics, MedImmune, Mirati, Newlink Genetics, Novartis, Plexxikon, Roche, Rubius, Takeda, Trovagene; ownership interest: Lilly.